Aenova's Swiss Caps USA Names Brad Carlson Vice President of Marketing and Sales

Aenova's Swiss Caps USA Names Brad Carlson Vice President of Marketing and Sales

Miami, Florida; October 1, 2012 – Aenova, a leading provider of development and manufacturing services for medicines and dietary supplements has named Brad Carlson as its new Vice President of Marketing & Sales for the Americas, effective October 1, 2012.  Mr. Carlson brings more than 20 years of life science industry experience to Aenova.

In his role as Vice President of Marketing & Sales, Mr. Carlson will report directly to Hans Engels, Chief Executive Officer of Aenova's Swiss Caps USA Inc.  Mr. Carlson, will be in charge of Marketing and Sales of North, Central and South America for Aenova.  He will be managing and increasing Aenova's network of sales and customer service representatives and distributors.

"Brad is an experienced leader with an impressive track record in the life science industry, and is renown for his attention to customer service and quality.  His ability to expand our sales rep., customer service and distribution team further strengthens our ability to meet the needs of our customers, grow sales and our brand," noted Hans Engels, CEO of Aenova's Swiss Caps USA."

Before joining Aenova / Swiss Caps USA, Mr. Carlson was Vice President of Marketing & Sales for two divisions of DSM N.V., where he also was responsible for Business Development, Quality Assurance and Packaging functions.  Prior to his assignments with DSM, Mr. Carlson held a variety of business and technical roles with life science organizations such as Glaxo Wellcome and Johnson & Johnson.

Mr. Carlson has BS in Packaging Science from Rochester Institute of Technology.

About Aenova

Aenova Holding GmbH was established in 2008 following the merger between two prominent medium-sized companies: Dragenopharm Apotheker Püschl GmbH and SWISS CAPS AG. The Aenova Group is now one of the leading manufacturers and suppliers of medicines and dietary supplements in oral dosage forms, such as soft gelatine capsules, hard capsules, tablets, film-coated tablets, dragées and effervescent tablets for the pharmaceutical and healthcare industry. The group has an annual turnover of around EUR 250 million and employs 1600 people at its sites in Germany (Tittmoning and Bad Aibling), Switzerland (Kirchberg, Muttenz and Bioggio), France (Lyons), Romania (Cornu) and the USA (Miami). The Aenova Group, which has its headquarters in Pähl,

offers its customers a complete portfolio of services, ranging from development,

procurement of raw materials, production and analysis through to packaging and logistics.

 

For further press information, please contact:

Söllner Communications AG

Dominik Herrmann

Rosenkavalierplatz 5

81925 Munich

Tel.: ++ (0) 89 / 41 94 73 13

Fax: ++ (0) 89 / 41 94 73 26

E-Mail: [email protected]

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.